Dulaglutide ameliorates hypertensive nephropathy in rats via preserving renal function's biomarkers, restoring tissue redox balance, increasing the anti-inflammatory marker IL-10 and decreasing the inflammatory marker TNF-α, elevating the renoprotective PPARγ gene expression, amending renal vasculopathy and glomerular injury, decreasing fibrosis, and increasing the immunohistochemical expression of eNOS and VEGF. The gene discussed is PPARG; the disease is hypertensive nephropathy.